In Brief: PLC Systems
This article was originally published in The Gray Sheet
Executive Summary
PLC Systems: Six month follow-up data from transmyocardial revascularization study of 100 patients from 12 U.S. clinical sites shows that firm's Heart Laser reduces angina class compared to medical therapy. TMR reduced average angina class from 3.7 to 1.7; drug therapy increased angina class to 3.9 on average. Mortality in the TMR group was 63% thus far in the TMR group. PLC has used this data and the one-year data from another patient study to "satisfy the FDA's request for premarket data." The firm has a PMA pending at FDA for use of the laser to treat patients without other treatment options...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.